KRAS G12C – A Key Emerging Biomarker in the Pathologic Evaluation of NSCLC
Learn about the rapidly evolving landscape of biomarkers in NSCLC, including the KRAS G12C mutation which occurs in 13% of patients with NSCLC.
KRAS G12C
KRAS G12C: Taking on one of cancer research's toughest challenges
Learn about KRAS and KRAS G12C mutations in cancer.
KRAS G12C Biomarker Fact Sheet
Learn more about the importance of KRAS mutations in NSCLC, as well as the current guidance recommendations for biomarker testing.
Find KRAS G12C Website
13% of patients (1 in 8) with NSCLC have the KRAS G12C mutation, yet many go undetected. Learn more about why identifying these patients may be important.
BiTE® Technology
BiTE® Immuno-Oncology Platform
Learn about the mechanism of action and the potential promise of the BiTE® Immuno-Oncology Platform.
Discover the BiTE® Interactive Experience
An immersive and dynamic experience that explores multiple cancer environments and how BiTE® Technology can be used with the goal to target different tumor types.
DLL3 Target for the BiTE® Platform (Educational Booklet)
Learn more about this protein that is expressed on the surface of many tumor cells.
BiTE The Engager™
The latest educational resource on the BiTE® Immuno-Oncology Platform.
PSMA in mCRPC DSE Slide Deck
PSMA—A clinically validated target in metastatic castration-resistant prostate cancer (mCRPC).
Pipeline and Clinical Trials
CodeBreaK HCP Website
A clinical trial program for patients with non-small cell lung cancer (NSCLC) whose cancer has the KRAS G12C mutation.
CodeBreaK Video
Amgen's CodeBreaK program is actively recruiting patients with the KRAS G12C mutation for studies.
Amgen’s Oncology Pipeline Chart
A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with meaningful effects in serious diseases.
Amgen’s Oncology Pipeline Interactive
A comprehensive interactive resource for Amgen's oncology pipeline, including molecules, targets, malignancies, and clinical trials.
CTS Card
Learn more about the Phase 1 study evaluating the safety, tolerability and pharmacokinetics of AMG 757.